---
figid: PMC7039327__nihms-1561976-f0002
figtitle: B-cell receptor signaling triggers formation of a multicomponent “signalosome,”
  which can activate BTK, AKT, PI3K, PLCG2, and BLNK, and CD19, a coreceptor important
  for PI3K activation
organisms:
- NA
pmcid: PMC7039327
filename: nihms-1561976-f0002.jpg
figlink: pmc/articles/PMC7039327/figure/F2/
number: F2
caption: B-cell receptor signaling triggers formation of a multicomponent “signalosome,”
  which can activate BTK, AKT, PI3K, PLCγ2, and BLNK, and CD19, a coreceptor important
  for PI3K activation. Inhibitors target enzymes in this signaling pathway. Modified
  from Kipps et al.
papertitle: Targeted Therapy in Chronic Lymphocytic Leukemia.
reftext: Thomas J. Kipps, et al. Cancer J. ;25(6):378-385.
year: ''
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.937984
figid_alias: PMC7039327__F2
figtype: Figure
organisms_ner:
- Homo sapiens
redirect_from: /figures/PMC7039327__F2
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7039327__nihms-1561976-f0002.html
  '@type': Dataset
  description: B-cell receptor signaling triggers formation of a multicomponent “signalosome,”
    which can activate BTK, AKT, PI3K, PLCγ2, and BLNK, and CD19, a coreceptor important
    for PI3K activation. Inhibitors target enzymes in this signaling pathway. Modified
    from Kipps et al.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - BCR
  - RN7SL263P
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - BTK
  - LYN
  - SYK
  - BLNK
  - PLCG2
  - VAV1
  - VAV2
  - VAV3
  - RAC1
  - RNASE1
  - RAC2
  - RHOA
  - RHOG
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - KRAS
  - HRAS
  - NRAS
  - EPHB2
  - MAPK1
  - MAPK3
  - MTOR
  - RPTOR
  - PC
  - CHUK
  - IKBKB
  - IKBKG
  - IKBKE
  - TBK1
  - NFKB1
  - CD79A
  - CD79B
  - CD19
  - Ibrutinib
  - Acalabrutinib
  - Vecabrutinib
  - Zanubrutinib
  - Tirabrutinib
  - Fostamatinib
  - Ca
  - GS
---
